Today the Ontario Bioscience Innovation Organization (OBIO) announced its 2019 Capital Access Advisory Program (CAAP). Included in this year’s program is Empirica Therapeutics, which was launched by CCAB earlier this year. CAAP is designed to support “high-potential” Ontario companies to drive fundraising and lead to business and job growth. Read the detailed announcement.
Empirica Therapeutics will develop new therapeutics for glioblastoma, a difficult-to-treat brain cancer